永赢医药创新智选混合发起C(015916)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
85,352,028.18 |
-43,310,481.76 |
-46,424,480.35 |
-25,415,319.45 |
| 本期利润 |
400,643,218.05 |
-34,993,830.19 |
-54,979,480.86 |
-27,465,740.75 |
| 加权平均基金份额本期利润 |
0.50 |
-0.16 |
-0.23 |
-0.19 |
| 本期加权平均净值利润率(%) |
37.83 |
-17.56 |
-25.71 |
-18.27 |
| 本期基金份额净值增长率(%) |
68.97 |
-12.44 |
-18.33 |
-2.01 |
| 期末可供分配利润 |
-417,995,745.97 |
-51,990,687.61 |
-92,901,727.03 |
-47,123,782.30 |
| 期末可供分配基金份额利润 |
-0.24 |
-0.32 |
-0.36 |
-0.17 |
| 期末基金资产净值 |
2,704,548,024.57 |
146,465,541.98 |
217,764,665.37 |
283,414,585.34 |
| 期末基金份额净值 |
1.52 |
0.90 |
0.84 |
1.03 |
| 基金份额累计净值增长率(%) |
52.11 |
-9.98 |
-16.03 |
2.81 |
微信公众号
证券之星APP
基本资料
